The Juvenile Diabetes Research Foundation is conducting a health economics study of continuous glucose sensing and insulin delivery technologies, known as the artificial pancreas. The study is designed as a companion piece to clinical studies in order to provide sound empirical evidence on the potential costs and benefits of this new technology.

Findings from this study will provide evidence to inform decisions regarding benefits from, and coverage and reimbursement for, the new continuous glucose monitoring (CGM) technology. Findings from the clinical study, published in the New England Journal of Medicine, indicate that CGM is most effective in Type I diabetics 25 years of age or older.

The NORC team is working closely with clinicians and researchers at the University of Chicago's Division of Biological Sciences and the Center for Health and the Social Sciences.

Related Publications:

The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. 2008. "Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes." New England Journal of Medicine, September 8, 2008. (10.1056/NEJMoa0805017)